Akero Therapeutics Inc (NASDAQ:AKRO) At $18.60: What To Do?

In last trading session, Akero Therapeutics Inc (NASDAQ:AKRO) saw 1.07 million shares changing hands with its beta currently measuring -0.46. Company’s recent per share price level of $18.60 trading at $0.71 or 3.97% at ring of the bell on the day assigns it a market valuation of $1.04B. That closing price of AKRO’s stock is at a discount of -213.87% from its 52-week high price of $58.38 and is indicating a premium of 39.52% from its 52-week low price of $11.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.13 million shares which gives us an average trading volume of 1.07 million if we extend that period to 3-months.

Akero Therapeutics Inc (NASDAQ:AKRO) trade information

Upright in the green during last session for gaining 3.97%, in the last five days AKRO remained trading in the red while hitting it’s week-highest on Monday, 02/05/24 when the stock touched $18.60 price level, adding 11.55% to its value on the day. Akero Therapeutics Inc’s shares saw a change of -20.34% in year-to-date performance and have moved -11.34% in past 5-day. Akero Therapeutics Inc (NASDAQ:AKRO) showed a performance of -19.36% in past 30-days. Number of shares sold short was 7.6 million shares which calculate 6.36 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Akero Therapeutics Inc (AKRO) estimates and forecasts

Statistics highlight that Akero Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -57.28% of value to its shares in past 6 months, showing an annual growth rate of 1.74% while that of industry is 15.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -75.50% in the current quarter and calculating -65.50% decrease in the next quarter.

AKRO Dividends

Akero Therapeutics Inc is more likely to be releasing its next quarterly report between March 15 and March 19 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

On Key

Related Posts